<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336686</url>
  </required_header>
  <id_info>
    <org_study_id>M102-21122</org_study_id>
    <nct_id>NCT01336686</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout</brief_title>
  <official_title>A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to
      placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in
      patients with gout.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum uric acid</measure>
    <time_frame>Baseline and end of treatment phase (4 wks)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Hyperuricemia</condition>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Arhalofenate 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arhalofenate 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arhalofenate</intervention_name>
    <description>Arhalofenate 400 mg once daily for 4 weeks</description>
    <arm_group_label>Arhalofenate 400 mg</arm_group_label>
    <other_name>MBX-102</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arhalofenate</intervention_name>
    <description>Arhalofenate 600 mg once daily for 4 weeks</description>
    <arm_group_label>Arhalofenate 600 mg</arm_group_label>
    <other_name>MBX-102</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Matching placebo once daily for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>0.6 mg colchicine daily for flare prophylaxis</description>
    <arm_group_label>Arhalofenate 400 mg</arm_group_label>
    <arm_group_label>Arhalofenate 600 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Read and sign the informed consent after the elements of consent have been fully
             explained and all questions have been addressed, prior to any study procedures.

          -  Known gout patient (per criteria of the American Rheumatism Association for the
             classification of the acute arthritis of primary gout in Appendix 3)

               -  the sUA must be ≥ 8.0 mg/dL and ≤12 mg/dL

               -  if on ULT, the patients must agree to temporarily discontinue their existing ULT
                  and the sUA must be ≥ 8.0 mg/dL and ≤12 mg/dL after wash-out at Week -1

          -  Male or female, 18-75 years of age at Screening Visit

          -  All female patients must be surgically sterile or post-menopausal (at least 45 years
             of age with no history of menses for at least 2 years; or any age with no history of
             menses for at least 6 months and serum FSH ≥ 40 mIU/mL) or have a partner who has
             undergone vasectomy or must agree to use two medically accepted methods of
             contraception including a barrier method (see the list in Appendix 4) for the entire
             duration of the study unless reporting complete sexual abstinence.

          -  Female patients must not be pregnant or lactating

          -  Male patients with a female partner of child-bearing potential must agree to use
             condom or the partner must use a medically acceptable method of contraception for the
             entire duration of the study.

          -  Patients must have an estimated CrCl ≥ 60 mL/min as calculated by the Cockcroft-Gault
             method

          -  Serum creatinine value must be ≤ 1.1 mg/dL in females and ≤ 1.3 mg/dL in males

          -  Patients must have liver function tests ≤ 1.5X ULN for AST, ALT and T-bilirubin, ≤ 2X
             ULN for ALP, ≤ 3X ULN for GGT; and ≤ 3X ULN for CK

          -  All other clinical laboratory parameters must be within normal limits or considered
             not clinically significant for participation in this study

          -  Electrocardiogram (ECG) must be normal, or if abnormal, considered not clinically
             significant for participation in this study

          -  Patients must have a systolic blood pressure ≤ 160 mm Hg and a diastolic blood
             pressure ≤ 90 mm Hg; known hypertensive patients controlled with medication other than
             thiazide diuretics (BP reading as above) may be included

        Exclusion Criteria:

          -  Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder,
             or organ transplant).

          -  Known patient with xanthinuria

          -  History of documented or suspected kidney stones

          -  Over producers of uric acid as evidenced by 24-hour urinary uric acid &gt; 800 mg (on
             normal unrestricted diet)

          -  Known infection with the human immunodeficiency virus (HIV) or history of viral
             hepatitis type B or C

          -  History of illicit drug or alcohol abuse within last 1 year

          -  History of significant pulmonary disease, upper GI bleeding, documented peptic ulcer
             disease (unless known H. pylori infection treated successfully without recurrence), or
             nephrotic syndrome within last 3 years

          -  All patients must not have had a stroke, TIA, acute myocardial infarction, congestive
             heart failure (NYHA Class II-IV), angina pectoris, coronary intervention procedure
             (including but not limited to angioplasty, stent placement, coronary
             revascularization), lower extremity bypass procedure, systemic or intracoronary
             fibrinolytic therapy within last 5 years

          -  Malignancy within the last 5 years (except resected basal cell carcinoma)

          -  Body mass index (BMI) &gt; 42 kg/m2

          -  Current or expected requirement for anticoagulant therapy (except for ≤ 325 mg/day
             aspirin and/or Plavix® 75 mg/day)

          -  Rheumatoid arthritis or other autoimmune disease requiring ongoing treatment

          -  Current or expected treatment with potent CYP3A4 inhibitors (See in Appendix 6),
             ranolazine, digoxin, cyclosporine, cyclophosphamide and other cytotoxic agents,
             sulphonylurea, thiazolidinedione, diuretic, atypical antipsychotic agents, and
             phenytoin

          -  Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs use to treat
             acute flares are permitted)

          -  Current or expected treatment with systemic corticosteroids (except topical,
             ophthalmic, intra-articular, or inhaled at a dose &lt; 1600 μg/day) other than to treat
             acute flares

          -  Known hypersensitivity to colchicine

          -  Treatment with any other investigational therapy within the 30 days prior to the
             Screening Visit, or patients who received at least one dose of blinded study drug
             while enrolled in any previous MBX-102 trial

          -  Any other condition that compromises the ability of the patient to provide informed
             consent or to comply with the objectives and procedures of this protocol, as judged by
             the investigator and/or medical monitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <disposition_first_submitted>February 19, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 30, 2015</disposition_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

